Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial

Dimopoulos, Meletios A.; Lonial, Sagar; Betts, Keith A.; Chen, Clara; Zichlin, Miriam L.; Brun, Alexander; Signorovitch, James E.; Makenbaeva, Dinara; Mekan, Sabeen; Sy, Oumar; Weisel, Katja; Richardson, Paul G.

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2019-07-24T16:06:29Z
dc.date.available	2019-07-24T16:06:29Z
dc.date.issued	2018
dc.identifier.issn	1097-0142
dc.identifier.uri	http://hdl.handle.net/10900/91179
dc.language.iso	en	en
dc.publisher	Wiley	de_DE
dc.relation.uri	http://dx.doi.org/10.1002/cncr.31680
dc.subject.ddc	610	de_DE
dc.title	Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_00770
utue.publikation.seiten	4032-4043	de_DE
utue.personen.roh	Dimopoulos, Meletios A.
utue.personen.roh	Lonial, Sagar
utue.personen.roh	Betts, Keith A.
utue.personen.roh	Chen, Clara
utue.personen.roh	Zichlin, Miriam L.
utue.personen.roh	Brun, Alexander
utue.personen.roh	Signorovitch, James E.
utue.personen.roh	Makenbaeva, Dinara
utue.personen.roh	Mekan, Sabeen
utue.personen.roh	Sy, Oumar
utue.personen.roh	Weisel, Katja
utue.personen.roh	Richardson, Paul G.
dcterms.isPartOf.ZSTitelID	Cancer	de_DE
dcterms.isPartOf.ZS-Issue	20	de_DE
dcterms.isPartOf.ZS-Volume	124	de_DE
utue.fakultaet	Universität Tübingen (ohne Fakultätsangabe)